Bone Metastasis Imaging with Copper-64-labeled Peptides

使用铜 64 标记肽进行骨转移成像

• 批准号: 7093541
• 负责人: Thaddeus J. Wadas
• 金额: $ 4.88万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7093541
• 关键词: bioimaging /biomedical imaging; bioluminescence; bone neoplasms; chemical stability; copper; integrins; laboratory mouse; metastasis; method development; neoplasm /cancer radionuclide therapy; peptides; positron emission tomography; postdoctoral investigator; radiopharmacology; radiotracer; receptor binding; vascular endothelium

DESCRIPTION (provided by applicant): The goal of this proposal is to address hypotheses regarding the imaging and therapy of cancer, in particular the targeting of the process of cancer metastasis with 64Cu-labeled peptides that target the avB3 integrin. The process of cancer metastasizing to the bone has been shown to be highly dependent on the presence of integrins, in particular the B3 integrin. Developing a bone imaging agent which specifically targets the avB3 integrin will allow clinicians to discriminately target sites of bone metastasis and would permit them to better determine the efficacy of a patient's treatment and plan additional therapy as needed. The specific aims, in brief, are (1) to develop 64Cu-CB-ligand conjugated peptides which possess enhanced in vivo stability. (2) Use micro PET imaging in conjunction with in vitro analysis to determine the binding affinity of these 64Cu-Cbligand conjugated peptides for the avB3 integrin, and to evaluate the use of the radiopharmaceuticals as PET bone metastasis imaging agents; and (3) to evaluate these 64Cu-CB-ligand conjugated peptides as therapeutic agents for bone metastasis.

描述（由申请人提供）：该提案的目标是解决有关癌症成像和治疗的假设，特别是使用靶向 avB3 整合素的 64Cu 标记肽来靶向癌症转移过程。癌症转移到骨的过程已被证明高度依赖于整合素的存在，特别是 B3 整合素。开发专门针对 avB3 整合素的骨显像剂将使临床医生能够有区别地针对骨转移部位，并允许他们更好地确定患者治疗的效果并根据需要计划额外的治疗。简而言之，具体目标是（1）开发具有增强的体内稳定性的64Cu-CB-配体缀合肽。 (2)利用显微PET成像结合体外分析测定这些64Cu-Cbligand缀合肽与avB3整合素的结合亲和力，并评估放射性药物作为PET骨转移显像剂的用途； (3)评估这些64Cu-CB-配体缀合肽作为骨转移治疗剂。